Why does injectable Oxymetholone have higher bioavailability than the oral tablet form?

Injectable androgens bypass the portal circulation, delivering active compound directly into systemic venous return without encountering hepatic enzymes first. Oral Oxymetholone must pass through the liver via the portal vein before reaching systemic circulation, where first-pass extraction reduces the fraction that achieves peripheral androgenic activity. Published AUC-based pharmacokinetic data estimate oral Oxymetholone bioavailability at approximately 56–70 %, while an equivalent injectable dose would theoretically reach near 100 % systemic availability.

What exactly is first-pass metabolism and how does it affect oral Oxymetholone absorption?

First-pass metabolism refers to the hepatic extraction of an orally ingested compound before it enters systemic circulation. After gastrointestinal absorption, Oxymetholone travels through the portal vein to the liver, where cytochrome P450 and other hepatic enzymes partially metabolise the parent molecule. The 17-alpha alkylation in Oxymetholone's structure partially resists this extraction, preserving a clinically meaningful fraction of the dose for systemic delivery — but a measurable percentage is still metabolised during that initial liver transit.

How does the absorption kinetics of oral Pro-Anadrol differ from an intramuscular androgen ester injection?

Oral Pro-Anadrol enters the bloodstream via gastrointestinal absorption followed by portal-hepatic transit, with plasma concentration rising as the surviving fraction clears the liver. An intramuscular ester depot releases compound slowly from the injection site into surrounding tissue, then into systemic venous return — completely skipping portal circulation. The result is that injectable routes tend to produce smoother, more complete systemic exposure per milligram administered, whereas oral dosing requires higher absolute doses to compensate for first-pass losses.

Can a 50mg/tab Oxymetholone tablet be split to adjust the dose, and does splitting affect bioavailability?

Pro-Anadrol tablets can be split if dose titration is required; however, splitting introduces a minor risk of uneven compound distribution across the two halves if tablet homogeneity is imperfect. Beligas Pharmaceuticals' GMP manufacturing and HPLC-confirmed tablet uniformity reduce that risk substantially. Splitting does not alter the route-of-administration bioavailability ceiling — whichever portion is swallowed still undergoes first-pass hepatic extraction. For precision dosing, using the 50 mg unit as a whole tablet within a structured protocol is the more reproducible approach.

Why is 50mg per tablet considered the highest practical concentration for oral Oxymetholone, and what advantage does this offer?

50 mg per tablet is the established ceiling concentration for oral Oxymetholone in pharmaceutical-grade products, matching the standard therapeutic unit used in clinical haematology trials for aplastic anaemia and wasting conditions. At this concentration, a single tablet provides a complete standardised dose without requiring multiple units per administration, reducing pill burden and improving compliance. Beligas Pro-Anadrol's 50-tab pack at this concentration delivers a full cycle's supply in one unit, simplifying inventory management compared to lower-concentration alternatives requiring multiple tablets per dose. (2) angle_used

Pharma Grade

Beligas Pharmaceuticals

Pro-Anadrol 50mg/tab 50 Tabletten by Beligas Pharmaceuticals

Name: Pro-Anadrol 50mg/tab 50 Tablets by Beligas Pharmaceuticals
Brand: Beligas Pharmaceuticals
SKU: ORA-OXYM-BEL-003
Price: 60.00 EUR
Availability: InStock
Rating: 4.5 (2 reviews)

4.5 (2 reviews)

Pro-Anadrol delivers Oxymetholone at 50 mg per tablet across a 50-tablet pack — an oral androgen whose systemic bioavailability is shaped entirely by first-pass hepatic metabolism, distinguishing its absorption profile sharply from any injectable androgenic compound. Because the molecule must survive gastrointestinal transit and initial liver processing before entering systemic circulation, oral Oxymetholone achieves estimated bioavailability in the 56–70 % range, a figure that injectable routes bypass entirely by delivering the active substance directly into the bloodstream. Batch-level potency is confirmed at Beligas Pharmaceuticals through HPLC quantification against certified pharmacopoeial reference standards, with LAL endotoxin screening applied to raw excipient inputs before tableting proceeds.

€60.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Delivers the full 50 mg pharmaceutical benchmark dose in a single tablet, eliminating multi-pill dosing complexity.
17-alpha alkylated structure specifically engineered to survive first-pass hepatic extraction and maintain systemic exposure.
HPLC-confirmed potency on every production lot ensures the declared 50 mg is a verified figure, not a nominal label estimate.
GMP-compliant tablet uniformity testing supports consistent dissolution and predictable gastrointestinal absorption across units.
50-tablet pack format provides a complete supply unit aligned with standard Oxymetholone cycle lengths.
LAL endotoxin screening of excipient inputs protects gastrointestinal mucosal integrity, supporting optimal absorptive surface function.
Beligas Pharmaceuticals' documented Pharma Grade release criteria mean batch-to-batch variability in absorption profile is minimised.

Phase	dosage	Note
Introductory / Bioavailability Calibration	50 mg/day (1 tablet)	Establishes individual hepatic first-pass response baseline; administer with a small meal to moderate absorption rate without significantly reducing bioavailability.
Main Anabolic Phase	100 mg/day (2 tablets, split dosing)	Split into two 50 mg administrations approximately 8–10 hours apart to maintain more stable plasma levels across the dosing window; splitting does not alter first-pass extraction per dose.
Advanced Protocol (experienced users only)	150 mg/day (3 tablets, split across 3 administrations)	Mirrors upper-range clinical trial doses used in haematology studies; hepatic monitoring becomes mandatory at this level given cumulative first-pass hepatic load.
Tapering / Cycle Close	50 mg/day (1 tablet) for final 7–10 days	Gradual reduction allows endogenous axis partial recovery to begin before PCT; bioavailability characteristics remain unchanged during taper.

Key takeaways

Understand that oral Oxymetholone bioavailability reaches approximately 56–70 % due to first-pass hepatic extraction.
Recognise injectable androgens bypass portal circulation, achieving superior per-milligram systemic availability.
Choose Pro-Anadrol's 50 mg/tab strength to minimise daily tablet count during higher-dose protocols.
Verify batch potency via HPLC confirmation before committing to a dosing protocol.
Account for first-pass losses when calculating effective oral Oxymetholone dose versus injectable equivalents.

Oral Bioavailability of Oxymetholone: What the Route of Administration Actually Changes

Pro-Anadrol is a pharmaceutical-grade oral androgen whose defining pharmacokinetic characteristic is the bioavailability ceiling imposed by first-pass hepatic extraction — a constraint that injectable androgens structurally avoid. When an Oxymetholone tablet is swallowed, the dissolved compound is absorbed across the gastrointestinal mucosa and transported via the portal vein directly to the liver before a single molecule enters systemic circulation. Hepatic enzymes perform partial extraction during this transit, meaning a fraction of the ingested dose is metabolised before it can exert peripheral androgenic or anabolic effects. Published pharmacokinetic estimates place oral Oxymetholone's absolute bioavailability at approximately 56–70 %, derived from comparative plasma AUC measurements in clinical pharmacology studies.

Injectable vs. Oral Route: Why the Difference Is Mechanistically Significant

An injectable androgen ester bypasses the portal circulation entirely: the compound enters the lymphatic system or systemic venous return from the injection site, achieving near-complete bioavailability before the liver encounters it. Compared to an equivalent molar dose delivered intramuscularly, an oral Oxymetholone dose must be calibrated upward to account for first-pass loss — which is precisely why therapeutic oral doses (50–150 mg/day in clinical anaemia protocols, per published haematology trial data) are substantially higher on a per-kilogram basis than dose equivalents seen in injectable anabolic regimens. The 17-alpha alkylation of Oxymetholone's structure resists hepatic deactivation at the C17 position, preserving enough parent compound to produce meaningful systemic exposure despite first-pass extraction; without that structural modification, oral bioavailability would approach negligible levels.

Tablet Integrity and Its Role in Achieving Consistent Bioavailability

Bioavailability is not determined by route alone — tablet dissolution characteristics directly govern how much Oxymetholone enters solution in the gastrointestinal tract and becomes available for absorption. Pro-Anadrol tablets are manufactured under GMP-compliant conditions, with each production lot subject to HPLC (High-Performance Liquid Chromatography) quantification confirming the declared 50 mg per tablet against certified reference standards. Tablet uniformity testing ensures that the dissolution profile remains consistent across units within a batch, preventing dose-to-dose variation from introducing unintended bioavailability fluctuations. Beligas Pharmaceuticals applies LAL (Limulus Amebocyte Lysate) endotoxin testing to excipient raw materials, ensuring that tablet binders contribute no pyrogenic contaminants that could compromise gastrointestinal mucosal integrity and thereby alter absorptive surface function.

Usage

Swallow each Pro-Anadrol tablet whole with 250–300 ml of water; do not crush, as surface area increase can accelerate dissolution kinetics unpredictably relative to the tested tablet format.
Administer with a light meal containing moderate fat content — food slows gastric emptying slightly, smoothing the absorption curve without meaningfully reducing the fraction surviving first-pass metabolism.
For split-dose protocols, space administrations by at least 8 hours to prevent overlapping plasma concentration peaks from compounding hepatic load during any single transit window.
Avoid grapefruit juice within 2 hours of dosing: grapefruit furanocoumarins inhibit CYP3A4 activity, which can alter the metabolic extraction ratio during first-pass transit and unpredictably shift plasma exposure.
Maintain a consistent daily administration time so that any variability in absorption caused by meal composition or gastrointestinal transit speed averages out across the cycle rather than accumulating directionally.
Track subjective and objective markers weekly — weight, strength metrics, and blood pressure — since the bioavailability-dependent plasma exposure directly drives both anabolic response magnitude and estrogenic/fluid-retention side-effect intensity.

Warnings

Contraindications: Pro-Anadrol is contraindicated in individuals with existing hepatic dysfunction, cholestatic liver disease, or elevated baseline liver enzymes (ALT/AST more than twice the upper limit of normal). Prostate carcinoma or breast carcinoma in male users represents an absolute contraindication. Females who are pregnant or may become pregnant must not use this compound. Individuals with a history of hypersensitivity to 17-alpha alkylated androgens should not initiate use.

Side Effects: Hepatotoxicity is the primary risk associated with oral 17-alpha alkylated compounds; Pro-Anadrol carries this risk proportional to dose and duration. Fluid retention and estrogenic-pattern effects (gynecomastia, oedema) can occur despite the compound's structural DHT lineage, likely via non-aromatase mechanisms. Blood pressure elevation, erythrocytosis (excess red blood cell production), and HDL suppression are documented in clinical trial data on therapeutic Oxymetholone use. Androgenic side effects including acne, accelerated scalp hair loss in predisposed individuals, and virilisation in females are dose-dependent.

Monitoring: Liver function panels (ALT, AST, ALP, bilirubin, GGT) should be assessed at baseline and at weeks 4 and 8 of any cycle. Complete blood count monitoring for erythrocytosis is recommended given Oxymetholone's documented haematopoietic activity. Lipid panels (HDL, LDL, total cholesterol, triglycerides) and blood pressure readings should be recorded at minimum every four weeks. Any elevation in liver enzymes exceeding three times the upper limit of normal warrants immediate cycle cessation.

PCT: Post-Cycle Therapy should commence within 72 hours of the final Pro-Anadrol tablet, taking into account that plasma clearance of oral Oxymetholone occurs over approximately 36–45 hours (based on half-life pharmacokinetic modelling). SERMs such as Tamoxifen (Nolvadex) or Clomiphene Citrate are the standard PCT agents for hypothalamic-pituitary-gonadal axis recovery. A minimum 4-week PCT protocol is recommended after cycles exceeding 6 weeks in duration. Liver support agents (TUDCA or UDCA at clinical dosing) should be continued for 4 weeks post-cycle to support hepatic recovery from 17-alpha alkylation-associated stress.

Frequently asked questions

Why does injectable Oxymetholone have higher bioavailability than the oral tablet form?: Injectable androgens bypass the portal circulation, delivering active compound directly into systemic venous return without encountering hepatic enzymes first. Oral Oxymetholone must pass through the liver via the portal vein before reaching systemic circulation, where first-pass extraction reduces the fraction that achieves peripheral androgenic activity. Published AUC-based pharmacokinetic data estimate oral Oxymetholone bioavailability at approximately 56–70 %, while an equivalent injectable dose would theoretically reach near 100 % systemic availability.
What exactly is first-pass metabolism and how does it affect oral Oxymetholone absorption?: First-pass metabolism refers to the hepatic extraction of an orally ingested compound before it enters systemic circulation. After gastrointestinal absorption, Oxymetholone travels through the portal vein to the liver, where cytochrome P450 and other hepatic enzymes partially metabolise the parent molecule. The 17-alpha alkylation in Oxymetholone's structure partially resists this extraction, preserving a clinically meaningful fraction of the dose for systemic delivery — but a measurable percentage is still metabolised during that initial liver transit.
How does the absorption kinetics of oral Pro-Anadrol differ from an intramuscular androgen ester injection?: Oral Pro-Anadrol enters the bloodstream via gastrointestinal absorption followed by portal-hepatic transit, with plasma concentration rising as the surviving fraction clears the liver. An intramuscular ester depot releases compound slowly from the injection site into surrounding tissue, then into systemic venous return — completely skipping portal circulation. The result is that injectable routes tend to produce smoother, more complete systemic exposure per milligram administered, whereas oral dosing requires higher absolute doses to compensate for first-pass losses.
Can a 50mg/tab Oxymetholone tablet be split to adjust the dose, and does splitting affect bioavailability?: Pro-Anadrol tablets can be split if dose titration is required; however, splitting introduces a minor risk of uneven compound distribution across the two halves if tablet homogeneity is imperfect. Beligas Pharmaceuticals' GMP manufacturing and HPLC-confirmed tablet uniformity reduce that risk substantially. Splitting does not alter the route-of-administration bioavailability ceiling — whichever portion is swallowed still undergoes first-pass hepatic extraction. For precision dosing, using the 50 mg unit as a whole tablet within a structured protocol is the more reproducible approach.
Why is 50mg per tablet considered the highest practical concentration for oral Oxymetholone, and what advantage does this offer?: 50 mg per tablet is the established ceiling concentration for oral Oxymetholone in pharmaceutical-grade products, matching the standard therapeutic unit used in clinical haematology trials for aplastic anaemia and wasting conditions. At this concentration, a single tablet provides a complete standardised dose without requiring multiple units per administration, reducing pill burden and improving compliance. Beligas Pro-Anadrol's 50-tab pack at this concentration delivers a full cycle's supply in one unit, simplifying inventory management compared to lower-concentration alternatives requiring multiple tablets per dose. (2) angle_used

Manufacturer

Beligas Pharmaceuticals' oral tablet portfolio is structured around a defined set of active compounds spanning multiple pharmacological classes — androgenic agents, selective androgen modulators, and ancillary performance compounds — and Pro-Anadrol occupies the high-dose oral androgen position within that lineup. What distinguishes the Pro-branded sub-line is the alignment of declared label concentrations with confirmed analytical values: the 50 mg Oxymetholone figure printed on each Pro-Anadrol blister strip is a chromatographically established number, not an approximated input-weight estimate. Each production lot is subject to HPLC quantification prior to release; reference standards used in that quantification are certified pharmacopoeial materials, not internal house standards of ambiguous traceability. Tablet uniformity and dissolution characteristics are tested as part of the same release framework, ensuring that the first-pass hepatic extraction profile a user experiences reflects the intended dose — because a tablet that delivers inconsistent Oxymetholone content would produce unpredictable plasma exposure even if the route-of-administration pharmacokinetics were perfectly understood. The Pro-Anadrol product line sits alongside other oral Pro-series compounds in Beligas' catalogue, all subject to identical release criteria, confirming that the analytical rigour applied here is systematic rather than product-specific.

Product details

Brand	Beligas Pharmaceuticals
Active ingredient	oxymetholone
Also known as	Anadrol, Anapolon, Oxymetholone, Pro-Anadrol, Beligas Pharmaceuticals Anadrol
Strength	50 mg
Form	Tabletten
Pack size	50 pieces
Item number	ORA-OXYM-BEL-003

Reviews

4.5/5

2 reviews

Rating: 5 out of 5 starsFabioVerified purchaseAug 3, 2026
Gained 14lbs in 4 weeks
started at 198lbs, finished week 4 at 212lbs running 100mg ed alongside 600mg test e per week. Strength through the roof - added 20kg to my squat in a month. Appetite was crazy, had to force myself to eat even more. Got bloods done after and hematocrit was 48% so kept an eye on it. Pumps in the gym were almost painful but I loved every second. Legit product
Rating: 4 out of 5 starsBradVerified purchaseJun 22, 2026
Great but pricey
Really solid results, put on about 10lbs in 3 weeks at 50mg per day. Pumps were absolutely mental, lower back pump was tough to deal with during deadlifts. Only gripe is it's a bit steep on price compared to some others I've used but the quality justifies it honestly. Would buy again.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Anapolon 50mg/tab 20 Tablets by Abdi Ibrahim

Lab Tested

Anapolon 50mg/tab 20 Tabletten by Abdi Ibrahim

Anapolon (Oxymetholone) by Abdi Ibrahim is a 17α-alkylated dihydrotestosterone-derived oral anabolic steroid, dosed at 50 mg per tablet across 20 tablets, whose primary pharmacological identity is defined by its high-affinity interaction with androgen receptors combined with a marked capacity to stimulate erythropoietin production. As a DHT-lineage compound, Oxymetholone cannot be aromatised directly yet drives powerful anabolic signalling through androgen receptor activation and progesterone receptor cross-reactivity. Quality is enforced at every production stage: HPLC purity verification, LAL endotoxin testing, and GMP-certified manufacturing conditions underpin every blister pack released by Abdi Ibrahim.

€20.00

Anapolon 50mg/tab 60 Tablets by Balkan Pharmaceuticals

HPLC Verified

Anapolon 50mg/tab 60 Tabletten by Balkan Pharmaceuticals

Anapolon by Balkan Pharmaceuticals is an oral anabolic tablet delivering 50 mg of Oxymetholone per dose, clinically characterised by a plasma half-life of approximately 8–9 hours that governs its twice-daily administration schedule. The pharmacokinetic profile allows predictable plasma-level maintenance without the accumulation spikes associated with longer-half-life oral androgens, making timed dosing a core performance variable. Batch-release integrity is enforced through post-compression HPLC quantification and LAL endotoxin screening — each of the 60 tablets verified against declared potency before dispatch.

€48.00

OxyTrex 25mg/tab 100 Tablets by Concentrex Labs

Purity Tested

OxyTrex 25mg/tab 100 Tabletten by Concentrex Labs

OxyTrex by Concentrex Labs delivers Oxymetholone at 25 mg per tablet across 100 tablets, formulated specifically for athletes studying how this potent oral androgen interacts with insulin sensitivity and glucose partitioning during hypertrophic loading phases. Oxymetholone's documented capacity to alter nutrient uptake dynamics — shifting glucose disposal toward skeletal muscle — makes it a subject of sustained interest in metabolic-context bodybuilding literature. Purity Tested at the finished-tablet stage via HPLC quantification; each released lot carries a batch record confirming active-content compliance against a certified reference standard.

€60.00

Oxymetholon 50mg/tab 100 Tablets by Dragon-Pharma

Batch Tested

Oxymetholon 50mg/tab 100 Tabletten by Dragon-Pharma

Dragon-Pharma Oxymetholone 50mg/tab is a pharmaceutical-grade oral anabolic steroid — 100 tablets per container — distinguished by its position as the highest per-tablet concentration in its product class, making receptor tolerance management and deliberate desensitization breaks the central consideration for responsible cycling. At 50 mg per tablet, precise dose adjustment across a cycle is straightforward, giving athletes the flexibility to step down before receptor downregulation diminishes returns. Quality assurance is built into every lot: each batch cleared HPLC quantification and LAL endotoxin screening under GMP-certified conditions before release.

€70.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00